A Comparative Study of the Detection of cAMP response element binding protein (CREB) in the Peripheral Blood of Alzheimer's Patients and the Healthy subjects as a Biomarker for the diagnosis of Alzheimer | Zendy

Ahmad Chitsaz | Zendy; Masih Falahatian | Zendy; Moneer Hadadian | Zendy

Open Access

A Comparative Study of the Detection of cAMP response element binding protein (CREB) in the Peripheral Blood of Alzheimer's Patients and the Healthy subjects as a Biomarker for the diagnosis of Alzheimer

Author(s) -

Ahmad Chitsaz,

Masih Falahatian,

Moneer Hadadian

Publication year - 2019

Publication title -

internal medicine and medical investigation journal

Language(s) - English

Resource type - Journals

ISSN - 2474-7750

DOI - 10.24200/imminv.v4i2.211

Subject(s) - creb , biomarker , medicine , dementia , alzheimer's disease , disease , peripheral blood , tau protein , depression (economics) , oncology , endocrinology , biology , gene , biochemistry , macroeconomics , transcription factor , economics

Alzheimer's disease is a neurodegenerative disease, which usually helps some biomarkers, such as amyloid proteins, to diagnose the disease. Therefore, the purpose of this study was to compare the expression of a protein binding protein to the adjuvant responder to circular adenosine monophosphate (CREB) in peripheral blood of patients to Alzheimer's and healthy elderly people as a biomarker for diagnosing Alzheimer. Materials and Methods: In this case-control study, 32 patients with Alzheimer's disease and 32 normal blood samples were taken. Using real time PCR, CREB expression was evaluated. Results: The mean CREB level in the case group was 0.89 ± 0.30 and in the control group was 1.01 ± 0.03. The mean of BDNF level in the case group was significantly higher than the control group (P 0.05). Conclusion: Reducing CREB levels in people with Alzheimer's disease can be a factor in diagnosis in comparison to healthy people.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research